(MedPage Today) — ATLANTA — An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal gastrointestinal adverse effects and no observed muscle loss, according to a phase II trial.
The oral…
Source link : https://www.medpagetoday.com/meetingcoverage/obesityweek/118398
Author :
Publish date : 2025-11-09 19:12:00
Copyright for syndicated content belongs to the linked Source.
